Hepatocellular carcinoma (HCC) is a common malignant tumor in the liver. Microvascular invasion (MVI) is one of the important risk factors affecting the recurrence and prognosis of HCC. Some scholars have predicted MVI through various imaging methods such as CT, MRI and PET, but has not yet reached a unified forecasting standard. Gadoxetate disodium（Gd-EOB-DTPA）is a novel hepatobiliary contrast agent. Peritumoral hypointension in hepatobiliary phase is of great value in predicting MVI, but the related studies are few. In this study, we used multiple parameters to analyze the value of Gd-EOB-DTPA enhanced MRI in predicting MVI qualitatively and quantitatively.
This abstract and the presentation materials are available to members only; a login is required.